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Due to the complex etiology of rheumatoid arthritis (RA), it is difficult to be completely 
cured  at  the  current  stage  although  many  approaches  have  been  applied  in  clinics, 
especially  the  wide  application  of  nonsteroidal  anti-inflammatory  drugs  (NSAIDs)  and 
disease-modifying antirheumatic drugs (DMARDs). New drug discovery and development 
via the recently discovered cholinergic anti-inflammatory and antinociceptive pathways 
should be promising. Based on the above, the nicotinic acetylcholine receptor agonists 
maintain the potential for the treatment of RA. Therefore, new therapeutic approaches may 
rise from these two newly discovered pathways. More preclinical experiments and clinical 
trials are required to confirm our viewpoint. 
KEYWORDS: rheumatoid arthritis, anti-inflammatory pathway, antinociceptive pathway, nicotinic 
acetylcholine receptor  
 
INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disorder that may affect many tissues and 
organs, which often leads to the destruction of articular cartilage and ankylosis of the joints[1]. Although 
the etiology of RA is still unknown, inflammation is the main pathological characteristic[2]. Consequently, 
to  inhibit  inflammation  is  of  primary  importance  for  the  treatment  of  RA[3].  Painkillers  and 
anti-inflammatory drugs have been widely used to relieve the symptoms of RA in clinics, especially the 
nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), Pan et al.: New Therapeutic Approaches for RA Treatment  TheScientificWorldJOURNAL (2010) 10, 2248–2253 
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which  are  used  to  inhibit  or  halt  the  underlying  immune  process  and  prevent  long-term  damage[4]. 
Nonetheless, the RA patient cannot be cured via simple treatment. Consequently, new therapeutic methods 
for RA are urgently needed. Based on our previous studies related to vagus nerve stimulation (VNS)[5] and 
the current literature review, we believe that the newly discovered cholinergic anti-inflammatory pathway 
and the antinociceptive pathway are potential targets for RA treatment . 
THE PROINFLAMMATORY CYTOKINES PLAY ESSENTIAL ROLE IN RA 
DEVELOPMENT   
Proinflammatory  cytokines  play  a  decisive  role  in  the  generation  of  the  inflammatory  and  destructive 
response[6]. More importantly, tumor necrosis factor alpha (TNF-α) is now targeted in the treatment of RA, and 
an antibody of TNF-α has proved to be effective[7]. Other cytokines are being tested and treated as targets 
for  RA  therapy  with  promising  results[8].  All  the  above  has  confirmed  the  importance  of  these 
proinflammatory cytokines in the pathological process of RA from the reverse side. It has been widely 
accepted that cytokines are involved in each phase of the pathogenesis of RA, by promoting autoimmunity 
(during  the  prearticular  phase),  by  maintaining  chronic  inflammatory  synovitis,  and  by  driving  the 
destruction of joints[9]. Among all the proinflammatory cytokines, TNF-α is the major one that presents in 
the rheumatoid joint and induces the synthesis and secretion from synovial fibroblasts of matrix-degrading 
proteases, interleukin-6 (IL-6), interleukin-8 (IL-8), and granulocyte-macrophage colony stimulating factor 
(GM-CSF)[10]. It has been found that TNF-α exerts its effects through binding to two receptors: the type I 
(p55) and type II (p75), which are found on immune, inflammatory, and endothelial cells[11]. More 
importantly,  Lam  et  al.  discovered  that  TNF-α  induced  osteoclastogenesis  by  directly  targeting 
macrophages in the presence of permissive levels of ligand for the receptor activator of NF-κB (RANKL), 
which may contribute to joint cartilage and bone destruction[12]. With further in-depth investigation, many 
factors have been discovered that may play important roles in TNF-α–induced osteoclastogenesis, e.g., 
TRAF2[13], IL-12[14], IL-7, IL-18[15], and IL-4[16]. Some of them are indispensable for activation of this 
process, while the others may have the opposite effect and inhibit osteoclastogenesis. Besides TNF-α, 
proinflammatory cytokines such as IL-1[17], IL-16[18], and high-mobility group B (HMGB)[19] play 
important roles as well. Therefore, a decreased inflammatory cytokine level may lead to ameliorated 
symptoms  of  RA.  Correspondingly,  an  inflammatory  cytokine–targeted  therapeutic  approach  is 
increasingly appreciated. 
PAIN IS AN IMPORTANT SYMPTOM OF RA   
Most RA patients suffer from pain as well as pain-related motion dysfunction. Actually, besides the 
inflamed joints, other normal tissues may be involved. Until now, the neurophysiological mechanisms 
underlying pain in RA remained unclear, while experimental models of inflammatory arthritis suggest that 
changes of neuronal sensitivity at both peripheral and central levels may be important[20]. When RA 
occurs,  within  the  joint,  inflammation  will  inevitably  lead  to  the  activation  of  articular  sensory 
receptors[21]. Moreover, Morris et al. reported that enhanced sensitivity of a population of sensory fibers 
partly contributed to the hyperalgesia of RA[22]. Since pain may lead to a series of complications and 
physical problems that will worsen the RA patients‟ condition, how to relieve pain has become another 
important issue. NSAIDs have been used as a therapeutic routine for the treatment of inflammation-induced 
pain in clinics. Side effects such as nausea, vomiting, diarrhea, constipation, decreased appetite, rash, 
dizziness, headache, drowsiness, etc. are inevitable. Opioids are another choice. It has been recognized that 
opioids mediate pain relief solely via centrally located opioid receptors in the brain and spinal cord, as well 
as by activating opioid receptors on peripheral sensory neurons[23]. Moreover, peripheral opioid receptor 
agonists have been found to inhibit inflammation and improve wound healing[24,25]. Therefore, opioids 
are frequently prescribed analgesics for patients suffering from rheumatic disease–induced pain, including Pan et al.: New Therapeutic Approaches for RA Treatment  TheScientificWorldJOURNAL (2010) 10, 2248–2253 
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RA[26]. The unwanted side effects, e.g., nausea, constipation, dizziness somnolence, and vomiting, greatly 
limit their application as well. Consequently, it is necessary to explore new drugs for the treatment of 
inflammation-induced pain.  
HOW DO THE CHOLINERGIC ANTI-INFLAMMATORY AND ANTINOCICEPTIVE 
PATHWAYS WORK? 
The „„cholinergic anti-inflammatory pathway‟‟, first reported by Tracey[27], is recognized as the efferent 
arm of the inflammatory reflex. In the preliminary research, the cholinergic anti-inflammatory pathway was 
activated by direct electrical stimulation of the efferent vagus nerve, which may inhibit the synthesis of 
TNF in liver, spleen, and heart, and attenuate serum concentrations of TNF during endotoxemia[28]. With 
more in-depth study, the α7 nicotinic acetylcholine receptor (α7 nAChR) was found to be the molecular 
dovetail  between  the  cholinergic  nervous  system  and  the  innate  immune  system[29],  which  mainly 
expresses on the membrane of immune cells, including monocytes, macrophages, T and B lymphocytes, 
and dendritic cells[16]. Moreover, in RA patients, α7 nAChR was found in the inflamed synovia[30]. 
Simultaneously, it has been reported that tissue macrophages, but not circulating monocytes, produce most 
of the TNF during an excessive inflammatory response[27]. Therefore, most of the recent research focused 
on the effect of α7 nAChR on the activity of macrophages. When the cholinergic receptor, which lies on the 
membrane  of  the  macrophage,  combines  with  its  ligand,  the  synthesis  of  proinflammatory  cytokines 
(TNF-α, IL-1, and IL-18), but not anti-inflammatory cytokines (such as IL-10), will be inhibited[28]. 
During this process, signaling transduction pathways, such as JaK2-STAT3, were involved[31,32]. In 
detail, nicotine may activate nAChRs, and Jak2 was recruited to the α7 subunit of the nAChR and was 
phosphorylated  after  nicotine  binding,  leading  to  phosphorylation  of  STAT3. Moreover,  Niziri  et  al. 
reported the immune modulation effect of α7 nAchR via suppression of Th1 and Th17 responses, which 
even deepened the current mechanism research[33]. It is interesting that α4β2 nAChR was reported to share 
a  similar  anti-inflammatory  function  as  α7  nAChR,  which  broadens  our  knowledge  concerning  the 
cholinergic anti-inflammatory pathway[34].  
Besides  the  anti-inflammatory  effect,  the  nAChRs  have  been  found  to  have  antinociceptive 
efficacy[35], which has been proven by a variety of species and pain tests[36]. Further studies indicated that 
nAChRs are expressed in a variety of CNS loci, e.g., medulla[37], midbrain[38], the thalamus, and the 
pedunculopontine tegmental nucleus[39]. Both α4β2 and α7 nAChRs are essential subtypes contributing to 
the cholinergic antinociceptive efficacy. Rowley et al. reported that nicotine, which is regarded as an 
agonist of α4β2 and α7 nAChRs, exerts antinociceptive efficacy in a mouse model of postoperative pain via 
reducing nociceptive input to the superficial and deep dorsal horn[40]. From the opposite side, blocking α7 
nAChR using α-BGTX resulted in decreased antinociceptive effects of α7 nAChR agonists, e.g., DMXB 
and  4-OH-DMXB  l[41].  Therefore,  nAChRs  are  the  main  factor  that  contributes  to  cholinergic 
anti-inflammatory and antinociceptive effects. 
WHAT HAS BEEN DONE AND NEEDS TO BE DONE  
Rheumatologists and orthopedic surgeons have turned their vision toward the treatment of RA using the 
cholinergic  anti-inflammatory  pathway[42,43,44,45].  More  importantly,  α7  nAChR  was  found  in  the 
synovial  tissue  of  RA  patients,  which  even  increased  the  feasibility  of  curing  RA  by  activating  the 
cholinergic anti-inflammatory pathway[30,46]. As to the therapy of RA, to our current knowledge, no 
report was found using the antinociceptive pathway, which should be strengthened in the future research. 
On the other hand, clinical proof-of-principle studies will be required to determine if nAChR agonists are 
active in pathological pain and inflammation conditions. We are pleased to know that such work is in 
process. A clinical trial entitled “Anti-Inflammatory Effects of GTS-21 After LPS” has been ongoing since 
October 30, 2008 (http://clinicaltrials.gov/ct2/show/NCT00783068). However, more clinical trials are to be Pan et al.: New Therapeutic Approaches for RA Treatment  TheScientificWorldJOURNAL (2010) 10, 2248–2253 
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expected after strictly designed in vivo and in vitro experiments obtain ideal results. That is our struggle in 
the future. 
PROSPECT  
Based  on  the  above  analysis,  nicotinic  cholinergic  receptors  are  potential  therapeutic  targets  for  the 
treatment of RA via activation of cholinergic anti-inflammatory and antinociceptive pathways (Fig. 1). 
Therefore,  the  agonists  of  nicotinic  cholinergic  receptors  are  expected  to  contribute  to  the  symptom 
amelioration of the RA patient. To achieve this goal, as we have mentioned in our previous paper, a 
three-step strategy should be considered[47]. First, the best candidate of nAChR agonists should be selected 
and the therapeutic effect should be confirmed. Second, the preclinical experiments should be performed. 
Third, strict phase I to phase III clinical trials are required that will provide stronger evidence for the 
potential application of such drugs in the future. 
 
FIGURE 1. The diagrammatic illustration of the potential application of cholinergic anti-inflammatory and antinociceptive pathways. 
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